Liver Disease Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

The Liver Disease Therapeutics Market By Treatment Type (Anti-Viral Drugs, Targeted Therapy, Immunosuppressant Drugs, Immunoglobulin, Vaccines, And Others), and geography is expected to grow at a steady CAGR forecast till 2028 owing to increased alcohol consumption associated with causing liver damage and increasing research and development activities.

The demand for liver disease therapeutics is primarily being boosted by the increasing number of people with liver diseases, the rise in alcohol consumption, and bad eating habits among others. Furthermore, the liver disease therapeutics market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the liver disease therapeutics market during the forecast period from 2023-2028.

Liver Disease Therapeutics Market Dynamics:

The increased consumption of alcohol across the world is expected to drive the growth of the peptide therapeutics market. For instance, as per the data provided by the Organization for Economic Co-operation and Development (OECD) 2023, Germany witnessed 10.6 litres/per capita consumption of alcohol among people aged 15 and above in 2019 and France reported 10.4 litres/per capita consumption of alcohol in 2020 by people aged 15 and above.

The above-mentioned source further mentioned about 9.7 litres/per capita and 7.9 litres/per capita alcohol consumption among individuals aged 15 and above in the United Kingdom and South Korea respectively in 2020.

The source mentioned above said that Latvia reported the highest consumption in 2019 (12.9 litres), followed by the Czech Republic, Austria, France, Hungary, Lithuania and Slovenia, all with over 11 litres per person.

The increasing normalization of consumption of alcoholic drinks at family and communal gatherings, casual outings, and other occasions, rising urbanization, increasing levels of disposable income, increased access, and advertising among other factors have contributed to the increased consumption of alcohol across nations. Individuals going through stress and depression often opt for drinking alcohol to get temporary relief.

However, excess intake of alcohol can cause liver damage. Alcoholic fatty liver disease, alcoholic hepatitis, and cirrhosis are some of the major liver diseases resulting from the misuse of alcohol. Depending upon the severity of the liver damage and considering other factors such as age, weight, and others healthcare professionals may prescribe a range of liver disease therapeutics thereby driving the market growth.

However, stringent regulatory approval processes and side effects associated with various liver disease therapeutics may restrict the growth of the overall liver disease therapeutics market.

Liver Disease Therapeutics Market Segment Analysis:

Liver Disease Therapeutics Market by Treatment Type (Anti-Viral Drugs, Targeted Therapy, Immunosuppressant Drugs, Immunoglobulin, Vaccines, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the application segment of the liver disease therapeutics market, the anti-viral drugs, category is expected to amass a significant revenue share in the year 2022.

This can be ascribed to the high incidence of virus-infected liver diseases, including hepatitis, and the efficacy of antiviral treatment for their treatment and management.

Because chronic hepatitis B virus (HBV) infection can lead to cirrhosis and hepatocellular carcinoma (HCC), which raise mortality and morbidity rates in people, it continues to be a major global public health concern.

Antiviral drugs are a type of medicine used to treat hepatitis. These are frequently used to prevent the hepatitis B virus and its long-term side effects, such as liver damage and impairment. They function by reducing the body's concentration of HBV (hepatitis B virus) and the chance of developing cirrhosis and hepatocellular carcinoma. Some of the FDA-approved drugs include Mavyret, Zepatier, and Vosevi.

Being safe and effective these drugs have been widely used for many years for patients with signs and symptoms of moderate-to-severe liver impairment or other serious liver problems.

Therefore, owing to the above-mentioned factors, the anti-viral category is expected to register significant growth, thereby driving the growth of the overall liver disease therapeutics market during the forecast period.

North America is expected to dominate the overall Liver Disease Therapeutics Market:

Among all the regions, North America is estimated to account for the largest share of the liver disease therapeutics market in the year 2022. Owing to the significance of key growth factors such as the changes in lifestyles, like drinking more alcohol and eating less healthily, have also made liver disease more common. Over the next few years, the regional market is expected to grow because patients are becoming more aware of their health and because new products are being made to meet unmet medical needs.

According to the National Institute on Alcohol Abuse and Alcoholism 2023, in the United States around 29.5 million people aged between 12 and older (10.5% in this age group) had Alcohol Use Disorder (AUD) in 2022. This included 17.4 million males aged 12 and older (12.6% in this age group) and 12.2 million females aged 12 and older (8.5% in this age group).

As per the source mentioned above, about 753,000 US adolescents having their aged between 12 and 17 had AUD in 2022.

Coupled with the factors mentioned above, the growing awareness of liver disease among US citizens as a result of the rise in the number of initiatives and programs by government and non-government organizations in the region is also going to assist in the market growth of liver disease therapeutics. For example, a national public health campaign named Think Liver Think Life™ by the American Liver Foundation aims to ensure every American understands their risk for liver disease, receives the appropriate screening and care coordination and feels well-informed and supported throughout their liver journey. Such initiatives assist people to receive proper diagnosis as well as treatment in the form of liver disease therapeutics for faster recovery.

Thus, the above-mentioned factors are likely to propel the growth of the liver disease therapeutics market in the region during the forecast period from 2023-2028.

Liver Disease Therapeutics Market Key Players:

Some of the key market players operating in the liver disease therapeutics market include AbbVie Inc., GSK, F.Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Inc., Astellas Pharma Inc., Merck & Co., Inc., Alnylam Pharmaceuticals, Inc., Sanofi, GSK plc, and Others

Recent Developmental Activities in the Liver Disease Therapeutics Market:

• In January 2024, Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo) announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
• In March 2019, HemoShear Therapeutics, LLC, a privately held biotechnology company, announced an extension of its partnership with Takeda Pharmaceutical Company Limited to discover and develop additional novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH).

Key Takeaways from the Liver Disease Therapeutics Market Report Study

• Market size analysis for current liver disease therapeutics market size (2022), and market forecast for 5 years (2023-2028)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global liver disease therapeutics market.
• Various opportunities available for the other competitors in the liver disease therapeutics market space.
• What are the top-performing segments in 2022? How these segments will perform in 2028?
• Which are the top-performing regions and countries in the current liver disease therapeutics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for liver disease therapeutics market growth in the coming future?

Target Audience who can be benefited from this Liver Disease Therapeutics Market Report Study

• Liver Disease Therapeutic product providers
• Research organizations and consulting companies
• Liver Disease Therapeutics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in liver disease therapeutics
• Various End-users who want to know more about the liver disease therapeutics market and the latest developments in the liver disease therapeutics market.

Frequently Asked Questions for the Liver Disease Therapeutics Market:

1. What are liver disease therapeutics?
Liver disease therapeutics are medicines that are used to treat liver diseases preventing further liver damage.

2. What are the drivers for the global liver disease therapeutics market?
The demand for liver disease therapeutics is primarily being boosted by the increasing number of people with liver diseases, the rise in alcohol consumption, and bad eating habits among others. Furthermore, the liver disease therapeutics market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the liver disease therapeutics market during the forecast period from 2023-2028.

3. Who are the key players operating in the global liver disease therapeutics market?
Some of the key market players operating in the liver disease therapeutics market include AbbVie Inc., GSK, F.Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Inc., Astellas Pharma Inc., Merck & Co., Inc., Alnylam Pharmaceuticals, Inc., Sanofi, GSK plc, and Others.

4. Which region has the highest share in the liver disease therapeutics market?
North America is expected to dominate the overall liver disease therapeutics market during the forecast period from 2023-2028. Owing to the significance of key growth factors such as the changes in lifestyles, like drinking more alcohol and eating less healthily, have also made liver disease more common. Over the next few years, the regional market is expected to grow because patients are becoming more aware of their health and because new products are being made to meet unmet medical needs.


This product will be delivered within 2 business days.